European Medicines Agency will decide whether the diabetes drug Actos should remain on the market

European Medicines Agency (EMA) – which is basically Europe’s FDA – will decide this month whether the diabetes drug Actos should remain on the market or not due to a possible link to bladder cancer.

Last month, France and Germany jumped ahead of the rest of the continent and suspended the use of Actos after a study indicated Actos users may have a higher risk of bladder cancer.

Here, the FDA says it will add information about the potential risk of bladder cancer after long-term use to the drug’s label, while keeping the product on the market at least for the time being.